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Abstract
Background: Aboriginal children in remote Australia have high rates of complicated middle ear disease
associated with Streptococcus pneumoniae and other pathogens. We assessed the effectiveness of
pneumococcal vaccination for prevention of otitis media in this setting.
Methods: We compared two birth cohorts, one enrolled before (1996–2001), and the second enrolled
after introduction of 7-valent pneumococcal conjugate and booster 23-valent polysaccharide vaccine
(2001–2004). Source populations were the same for both cohorts. Detailed examinations including
tympanometry, video-recorded pneumatic otoscopy and collection of discharge from tympanic membrane
perforations, were performed as soon as possible after birth and then at regular intervals until 24 months
of life. Analyses (survival, point prevalence and incidence) were adjusted for confounding factors and
repeated measures with sensitivity analyses of differential follow-up.
Results: Ninety-seven vaccinees and 51 comparison participants were enrolled. By age 6 months, 96%
(81/84) of vaccinees and 100% (41/41) of comparison subjects experienced otitis media with effusion
(OME), and by 12 months 89% and 88% experienced acute otitis media (AOM), 34% and 35% experienced
tympanic membrane perforation (TMP) and 14% and 23% experienced chronic suppurative otitis media
(CSOM). Age at the first episode of OME, AOM, TMP and CSOM was not significantly different between
the two groups. Adjusted incidence of AOM (incidence rate ratio: 0.88 [95% confidence interval (CI):
0.69–1.13]) and TMP (incidence rate ratio: 0.63 [0.36–1.11]) was not significantly reduced in vaccinees.
Vaccinees experienced less recurrent TMP, 9% (8/95) versus 22% (11/51), (odds ratio: 0.33 [0.11–1.00]).
Conclusion:  Results of this study should be interpreted with caution due to potential bias and
confounding. It appears that introduction of pneumococcal vaccination among Aboriginal infants was not
associated with significant changes in prevalence or age of onset of different OM outcomes or the
incidence of AOM or TMP. Vaccinees appeared to experience reduced recurrence of TMP. Ongoing high
rates of complicated OM necessitate additional strategies to prevent ear disease in this population.
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Background
Young Aboriginal children in remote Australia have a
24% prevalence of tympanic membrane perforation
(TMP) and 15%[1] to 24%[2] prevalence of chronic sup-
purative otitis media (CSOM). The World Health Organi-
zation states that CSOM prevalence greater than 4%
indicates a massive public health problem[3].
Among Aboriginal infants, Haemophilus influenzae, Strepto-
coccus pneumoniae, and Moraxella catarrhalis have been iso-
lated from 57%, 34% and 4% of TMPs respectively, with
H. influenzae and S. pneumoniae co-infection in 28% of
cases[4]. Pneumococcal serotypes associated with TMP
are 19A, 19F, 23F, 14 and 1[5]. The 7-valent pneumococ-
cal conjugate vaccine (7PCV) includes three of these: 19F,
23F and 14 as well as serotypes 4, 6B, 9V and 18C. Trials
of 7PCV suggest efficacy of 6% against acute otitis media
(AOM) in American and Finnish children[6,7] with
greater efficacy against more severe outcomes (9%[7] to
10%[6] against recurrent AOM and 23%[8] to 39%[9]
against tympanostomy procedures). Two studies have
reported 100% efficacy against TMP due to vaccine sero-
types, excluding 19F[8,10]. Efficacy against any TMP or
CSOM is unknown. We thought that 7PCV might be even
more effective in populations with a high burden of severe
otitis (Australian Aboriginal children and others with sub-
stantial prevalence of CSOM [11-14]). Pneumococcal vac-
cination for Aboriginal children in Australia began in late
2001. We compared: 1) time to develop otitis media with
effusion (OME) and other OM outcomes, 2) OM preva-
lence outcomes and 3) OM incidence outcomes in two
birth cohorts of Aboriginal infants, before and after intro-
duction of pneumococcal vaccination.
Methods
Study Setting
Two cohorts were enrolled from three Aboriginal commu-
nities on the Tiwi islands north of Darwin (population
2,029)[15]. We compared a cohort that received pneumo-
coccal vaccination (2001–2004) with a comparison
cohort from the same communities prior to vaccine avail-
ability (1996–2001).
Participants
The comparison, or before vaccine group, was enrolled in
a randomised controlled trial of long-term amoxicillin
versus placebo between 1996 and 2001 (OM-RCT)[16].
As subjects enrolled in the OM-RCT began randomised
therapy after detection of the first OME episode, the com-
parison group for the time to first OME outcome included
all subjects enrolled in the OM-RCT. For all other out-
comes, the comparison group comprised only those par-
ticipants assigned to placebo. The vaccinated group was
enrolled between 2001 and 2004, after catch-up vaccina-
tion for those less than 2 years of age, and introduction of
routine pneumococcal vaccination in July 2001.
Comparison group exclusion criteria were: age >12
months, gestation <34 weeks, penicillin sensitivity, long-
term antibiotic therapy, craniofacial abnormality, CSOM
and immunodeficiency[16]. Exclusion criteria for the vac-
cinated group were: age >4 months, gestation <34 weeks
and congenital abnormality.
Consent and Ethical Considerations
The mother or carer gave written informed consent for
each study. The Institutional Ethics Committee of Terri-
tory Health Services and Menzies School of Health
Research, and the Tiwi Health Board approved the studies.
Procedures
Comparison participants were enrolled as soon as possi-
ble after birth and examined every two weeks until OME
was detected. They were then randomised to amoxicillin
or placebo until middle ear status was normal. Children
received randomised therapy and monthly examinations
for an average of 5.2 months[16]. Vaccinees were also
enrolled as soon as possible after birth and examined
every two weeks until OME was detected, and then
monthly until 12 months of age. Both groups were exam-
ined at 12, 18 and 24 months of age or until study com-
pletion.
All participants received standard care, including vaccina-
tions, from community clinics. Vaccinees were scheduled
to receive 7PCV at 2, 4 and 6 months of age and 23-valent
polysaccharide vaccine (23PPV) at 18 months. The
research team provided additional clinical care if new
problems were identified during assessment. Medications
provided by the study and community clinic were super-
vised for the comparison group but not for vaccinees.
Standard antibiotic therapy for AOM among the vacci-
nated cohort was amoxicillin 50 mg/kg/day for 7 days
(research team) and 300 mg twice daily for 5 days (com-
munity clinic), and for the comparison group, amoxicillin
50 mg/kg/day for 5 days (research team) and 125 mg
thrice daily for 5 days (community clinic).
Assessment involved direct and video-recorded pneu-
matic otoscopy, tympanometry (GSI 38 Auto-Tymp Gray-
son-Stadler) and review of clinic records. Two
independent, unblinded assessors standardised video
diagnoses in the two cohorts. Consensus between asses-
sors' video diagnoses was required in both studies and if a
diagnosis in the 1996–2001 cohort was changed. If asses-
sors disagreed a third assessor resolved the decision. Data
were recorded using standard forms.BMC Pediatrics 2009, 9:14 http://www.biomedcentral.com/1471-2431/9/14
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Definitions
￿ OME: Type B tympanogram with neutral or mild bulg-
ing of the TM.
￿ AOM: Moderate or marked bulging of the TM. New epi-
sodes were defined when the preceding examination was
OME or normal.
￿ TMP: Discharge through a perforation for <6 weeks or
pus in the auditory canal. New episodes were defined
when the preceding examination was AOM, OME or nor-
mal.
￿ CSOM: TMP with discharge for 6 weeks or greater.
Microbiology of Tympanic Membrane Perforations
Microbiological techniques were the same for both
groups. Aluminium-shafted, cotton-tipped swabs (Dis-
posable Products, Australia) of perforation discharge were
collected through, or from as close as possible to, the site
of perforation. Specimens were transported and stored
frozen as recommended for pneumococcal carriage stud-
ies[17]. Aliquots (10 μl) were cultured on selective media
and incubated overnight at 37°C in 5% CO2. S. pneumo-
niae was confirmed with serotyping by the Quellung reac-
tion, H. influenzae by dependence on X and V factors, and
M. catarrhalis by colony morphology, Gram stain and oxi-
dase production.
Statistical Analysis
Vaccinee and placebo recipient data were compared, apart
from the time to first OME outcome, for which compari-
son group data were included from all randomised sub-
jects in the OM-RCT; i.e. before detection of OME and
subsequent randomisation.
For time to first OME and AOM, data were included if the
first examination was before 4 months of age. For time to
first TMP and CSOM, data were included if the first exam-
ination was before 6 and 9 months of age respectively.
Participant data were censored if the duration between
consecutive examinations was greater than 2 months.
Examinations after 24 months of age were excluded. To
explore potential effects of unobserved clinical events
because of differential follow-up, sensitivity analyses were
performed including different ages at first examination
(range less than 4 months to any age) and examination
intervals (less than 2 to 6 months).
Analyses of pathogens associated with new perforation
(specimen collected <28 days following new perforation)
were performed per ear rather than per child. Recurrent
(>1 episode in one ear) or bilateral perforation during fol-
low-up were examined by log-linear modelling.
Time to first event outcomes used Kaplan-Meier curves
and Cox proportional hazards models. Incidence out-
comes used Poisson regression with estimates adjusted for
repeated measures using generalised estimating equa-
tions. A priori analysis included adjustment for 'rate of
non-respiratory illness' (incidence of presentations for
diarrhoea, anaemia, failure to thrive, skin sores, scabies
and fungal infection) as a measure of general ill health
between studies. Other potentially confounding variables
(gender, age at first examination, rate of well and sick
clinic visits, rate of prior antibiotic prescription, birth
weight, delayed immunisation (>1 month after due date)
were included in forward stepwise modeling if p-values
were less than 0.10. Statistical significance was the 5%
confidence level. Assuming a baseline median time to
OME of 60 days[18], an alpha level of 0.05 with 100 vac-
cinated and 80 comparison participants, the comparison
had power of 0.77 to detect a clinically important differ-
ence of 20 days. Assuming a baseline cumulative propor-
tion experiencing TMP of 50%, alpha of 0.05 with 100
vaccinated and 50 comparison participants, the compari-
son had power of 0.82 to detect an expected reduction of
50% to a cumulative proportion of 25%.
Role of the Funding Source
The National Health & Medical Research Council of Aus-
tralia funded the RCT. Wyeth Australia funded the vaccine
study. Neither was involved in study design, collection,
analysis, interpretation of data, writing or submission of
the report.
Results
Enrolment and Comparability of Groups
Greater than 80% of infants in the population after vac-
cine introduction were enrolled and 54%[16] were
enrolled in the before vaccination cohort. There were 97
vaccinees (mean follow-up, 470 days [range 35–728]; Fig-
ure 1) and 51 comparison children randomised to pla-
cebo (mean follow-up, 472 days [range 154–727]). Mean
number of examinations to age 24 months was 10.9
(range 1–22) for vaccinees and 9.5 (range 3–17) for com-
parison participants. Vaccinees began follow-up at a
younger age than comparison participants but by eight
months of age similar proportions of each group had
begun follow-up (Figure 1). Among vaccinees the third
dose of 7PCV was given at a mean age of 6.7 months
(range 4.2, 13.6) and at greater than 8 months for 14/93
(15%). Sex distribution, birth weight and maternal age
were similar among the comparison groups (Table 1).
Compared to comparison participants in the first 6
months of life, vaccinees had reduced rates of lower respi-
ratory illness, were younger at first examination, had
fewer well clinic visits, and fewer were late for immunisa-
tion (Table 2). Although the reduced rate of lower respira-BMC Pediatrics 2009, 9:14 http://www.biomedcentral.com/1471-2431/9/14
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tory illness among vaccinees may be attributable to
pneumococcal vaccination, and not potential confound-
ing factors, the other characteristics in Table 2 may still be
used for comparison of the two groups.
Comparing census data from 2001 and 1996, there were
similar income levels, proportions of residents aged 0–4,
and rates of unemployment (data not shown). Average
household occupancy was lower in 2001 than 1996, 4.5
versus 5.1 occupants per house.[15,19]
Prevalence of Otitis Media Outcomes in the First Year of 
Life
By 2 months of age approximately 70% of both vacci-
nated and comparison participants had developed OME,
by 6 months virtually all had developed OME (Table 3).
By 12 months, approximately 90% in both groups had
documented AOM. The proportion of vaccinees experi-
encing TMP in the first 9 months of life was lower than
comparison participants, although by 12 months 35% of
both groups had experienced TMP. By age 12 months,
14% of vaccinees and 23% of comparison participants
had developed CSOM (Table 3). Seven children excluded
from the OM-RCT due to a diagnosis of CSOM at initial
assessment[16] were not included in this study, although
their exclusion may have reduced the proportion of com-
parison participants at risk of developing CSOM.
Time to First Otitis Media Outcomes
Time to first OME analysis included 90 vaccinees and 70
comparison participants. Univariate and multivariate
analyses showed time to first OME was not significantly
different by group (Table 4). Increased time to first OME
was associated with older age at first examination. Univar-
iate and multivariate analyses indicated that vaccination
had no effect on time to first AOM, TMP or CSOM (Table
4). Kaplan-Meier curves were similar for both groups (Fig-
ure 2).
Unadjusted, Multivariate, and Sensitivity Analyses of the 
Incidence of Acute Otitis Media and Tympanic Membrane 
Perforation
Analysis of AOM incidence included 90 vaccinees and 37
comparison participants. Unadjusted analysis showed
vaccination associated with an AOM absolute rate reduc-
tion (ARR) of 0.18 episodes per person-year (2.05 in com-
Table 1: Vaccinated and comparison group characteristics
Participant Characteristic Vaccinated
N = 97
Comparison
N = 51
Mean Difference or Odds Ratio (95% CI)
Sex (% Male) 45 (46%) 30 (59%) 0.61 (0.29, 1.27)
Birth weight (g) 2956 (n = 87) 3159 (n = 49) -203 (-409, 3)
Maternal age (years) 24.2 (n = 95) 23.0 (n = 49) 1.2 (-0.8, 3.1)
Birth weight was missing for 10 vaccinees and 2 comparison participants. Maternal age was missing for 2 vaccinees and 2 comparison participants.
Table 2: Clinical characteristics of vaccinated and comparison groups in the first 6 months of life
Clinical Characteristic Vaccinated
N = 94
Comparison
N = 41
Mean Difference or Odds Ratio (95% CI)
Mean Age at first examination (in days) 41 60 -18 (-31 – -5)
Well clinic visits 4.84 10.3 -5.48 (-7.21 – -3.75)
Sick clinic visits 6.95 8.90 -1.96 (-4.46 – 0.55)
Upper respiratory illnesses* 1.33 1.00 0.33 (-0.21 – 0.87)
Lower respiratory illnesses 0.98 3.21 -2.24 (-2.89 – -1.59)
Non-respiratory illnesses 2.80 2.71 0.09 (-1.06 – 1.24)
Diarrhoeal illnesses 0.62 0.85 -0.24 (-0.76 – 0.28)
Antibiotic prescriptions 3.54 4.51 -0.97 (-2.30 – 0.37)
Proportion Failure to thrive 5 (5%) 1 (2%) 2.25 (0.24 – 109)
External nasal discharge 27 (29%) 12 (29%) 1.02 (0.45 – 2.31)
Admitted to hospital 18 (19%) 9 (22%) 0.84 (0.32 – 2.37)
Late immunisation† 14 (15%) 18 (44%) 0.22 (0.09 – 0.56)
Tests positive for anaemia‡ 24% 36% -12 (-40 – 15)
Note: 3 vaccinated and 10 comparison participants were excluded from clinical comparison in the first 6 months of life as their first examinations 
occurred at greater than 6 months of age.
*Upper respiratory illness includes OM or other upper respiratory tract infections.
†Immunisation greater than one month after due date.
‡Anaemia defined as haemoglobin level less than 9 g/dL.BMC Pediatrics 2009, 9:14 http://www.biomedcentral.com/1471-2431/9/14
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parison and 1.87 in vaccinated participants; incidence rate
ratio (IRR): 0.91 [95% CI: 0.64–1.29]). Increased AOM
incidence was associated with the a priori adjustment var-
iable, non-respiratory illness rate, which was included in
multivariate modelling (data not shown). Vaccination
was associated with an adjusted ARR of 0.20 episodes per
person-year (2.03 in comparison and 1.83 in vaccinated
participants; IRR: 0.88 [95% CI: 0.69–1.13]). Sensitivity
analysis including any age at first examination and less
than 4 month examination intervals (97 vaccinees, 51
comparison participants) resulted in a different adjusted
ARR of 0.40 episodes per person-year (2.02 in comparison
and 1.62 in vaccinated participants; IRR: 0.81 [95% CI
0.67–0.99]). Recurrent AOM (>1 episode) occurred in
45% (44/97) of vaccinees and 55% (28/51) of compari-
son participants (Table 5).
Analysis of the incidence of new perforation included 94
vaccinees and 41 comparison participants. Unadjusted
analysis showed vaccination associated with an ARR of
new perforation of 0.27 episodes per person-year (0.82 in
comparison and 0.55 in vaccinated participants; IRR: 0.68
[95% CI 0.40–1.14]). Increased incidence of new perfora-
tion was associated with increased antibiotic prescription
and non-respiratory illness rate (data not shown). Multi-
variate modelling showed vaccination associated with an
adjusted ARR of 0.28 episodes per person-year (0.75 in
comparison and 0.47 in vaccinated participants; IRR: 0.65
[95% CI: 0.38–1.10]). Sensitivity analysis including any
age at first examination and less than 4 month examina-
tion intervals (97 vaccinees, 51 comparison participants)
resulted in a different adjusted ARR of 0.36 episodes per
person-year (0.75 in comparison and 0.39 in vaccinated
participants; IRR: 0.51 [95% CI: 0.31–0.84]). Recurrent
perforation (>1 episode) occurred in 8% (8/97) of vac-
cinees and 22% (11/51) of comparison participants (odds
ratio: 0.33 [95% CI: 0.11–1.00]) (Table 5).
A lower risk in vaccinees of new perforation, but not
AOM, persisted throughout approximately 300 days of
follow-up (Figure 3).
Bilateral and Recurrent Tympanic Membrane Perforation
The number of participants experiencing unilateral or
bilateral perforation and single or multiple episodes of
perforation were analysed by log-linear modelling. Odds
of both left and right TMP during follow-up in vaccinees
were 0.41 [95% CI: 0.18–0.94) compared to comparison
participants. Similarly, vaccinees had lower odds of mul-
tiple perforations 0.40 [95% CI: 0.18–0.87).
Microbiology Outcomes
Discharge from new perforations was collected more
often from vaccinees than comparison participants (Table
6). Proportions of positive specimens (S. pneumoniae, H.
Enrolment and follow-up profile Figure 1
Enrolment and follow-up profile. Demonstrating num-
bers of participants entering and leaving follow-up at different 
ages.
                
Vaccinated Group
2001 – 2004 
Enrolled N=99 
First examination <4 months 
of age & included in time to first 
OME analysis n=90 (91%) 
Clinical assessment n=97 (98%)
Examined less than:
2 months of age n=75 (76%) 
4 months of age n=85 (86%) 
6 months of age n=94 (95%) 
8 months of age n=97 (98%)
Comparison Group 
1996 – 2001 
Enrolled N=126 
Randomised N=103 
First examination <4 months 
of age and included in time to first 
OME analysis n=70 (68%) 
Randomised to placebo n=51 
Clinical assessment n=51 (100%)
Examined less than:
2 months of age n=25 (49%) 
4 months of age n=37 (73%) 
6 months of age n=41 (80%) 
8 months of age n=48 (94%)
Examined greater than:
12 months of age n=36 (71%) 
15 months of age n=32 (63%) 
18 months of age n=27 (53%) 
Examined greater than:
12 months of age n=66 (67%) 
15 months of age n=57 (58%) 
18 months of age n=49 (49%) 
Table 3: Cumulative proportions of participants over time with 
different otitis outcomes
Outcome Age
(months)
Vaccinated
n/N (%)
Comparison
n/N (%)
OME 1 27/47 (57) 6/13 (46)
2 49/73 (67) 18/25 (72)
4 72/83 (87) 35/37 (95)
6 81/84 (96) 41/41 (100)
AOM 2 5/73 (7) 4/25 (16)
4 33/83 (40) 19/37 (51)
6 53/84 (63) 33/41 (80)
9 65/83 (78) 41/45 (91)
12 65/73 (89) 35/40 (88)
TMP 4 3/83 (4) 2/37 (5)
6 10/84 (12) 8/41 (20)
9 18/83 (22) 14/45 (31)
12 25/73 (34) 14/40 (35)
15 20/59 (38) 14/35 (40)
24 15/30 (50) 12/23 (52)
CSOM 6 1/84 (1) 3/41 (7)
*9 4/83 (5) 8/45 (18)
12 10/73 (14) 9/40 (23)
15 8/59 (14) 7/35 (20)
24 9/30 (30) 9/23 (39)
To minimise loss of case ascertainment the denominator includes only 
participants followed to the age of the given category.
*p < 0.05BMC Pediatrics 2009, 9:14 http://www.biomedcentral.com/1471-2431/9/14
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influenzae or M. catarrhalis) were similar in the two groups.
Proportions of positive specimens with serotypes
included in the 7PCV and serotype 6B were lower in vac-
cinees (Table 6). Predominant serotypes in the compari-
son group were 6B (5 cases), 23F, 19A, 16F and 11A (2
each). In the vaccinated group 19A, 19F and 16F were pre-
dominant (4 each), followed by 6B, 6A and 7C (2 each).
In the vaccinated group, vaccine-type pneumococci were
associated with 7 episodes of perforation which were dis-
tributed evenly throughout the duration of the study (data
not shown).
Discussion
This is the first report of the impact of pneumococcal vac-
cination on any TMP and the natural history of OM in a
high risk population. Introduction of vaccination was not
associated with large effects on the outcomes of primary
interest, delayed onset of OME and proportions of partic-
ipants experiencing TMP. We also found that infant pneu-
mococcal vaccination in remote Aboriginal communities
was associated with, albeit with marginal significance:
a) Little effect on cumulative proportions of participants
experiencing, or time to first episode of OME, AOM, TMP,
or CSOM.
b) A reduced proportion developing CSOM at 9 months
of age.
c) Trends towards reduced incidence of AOM and TMP in
the first 2 years of life.
d) Reduced recurrence of TMP.
In addition, the consistent relationship of cumulative haz-
ards for TMP between the groups, suggested that any effect
of three doses of 7PCV did not wane before 12 months of
age.
The lack of substantial benefit of pneumococcal vaccina-
tion for OM in this population is likely due to a combina-
tion of factors. Vaccination had little effect on the high
prevalence of H. influenzae infection or co-infections of H.
influenzae and S. pneumoniae. As with studies in Finland
and the US, vaccination did not prevent otitis associated
with serotypes 19F[7,8] and 19A[7] which were common
in our study. Unlike Finnish[7] and Czech Republic[20]
studies of AOM, our data indicate a trend towards
increased risk of TMP associated with vaccine-related sero-
types. The US also reports increased proportions of AOM
associated with vaccine-related and non-vaccine serotypes
in the post-7PCV era[21,22]. Increased invasive 19A dis-
ease has been noted in post-7PCV surveillance among
Alaska native[23] and Massachusetts children[24].
Although our findings do not support substantial replace-
ment OM disease due to H. influenzae, they are consistent
with US reports documenting potential H. influenzae
Table 4: Univariate and multivariate survival analyses of time to first event for different otitis outcomes, hazard ratios and 95% 
confidence intervals
Variable/s included in analyses OME AOM TMP CSOM
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Univariate
Vaccinated versus comparison group 1.17 (0.85 – 1.62) 0.80 (0.51 – 1.26) 0.84 (0.42 – 1.67) 0.57 (0.20 – 1.62)
Age at first examination (days) 0.98 (0.98 – 0.99) 1.00 (0.99 – 1.01) n/a n/a
Females/Males 0.79 (0.57 – 1.10) 1.06 (0.70 – 1.60) 0.99 (0.53 – 1.88) 0.36 (0.11 – 1.13)
Rate of non-respiratory illness* 1.09 (0.79 – 1.52) 1.08 (0.73 – 1.60) 1.07 (0.57 – 2.01) 0.98 (0.39 – 2.46)
Rate of prior antibiotic prescription* 0.71 (0.48 – 1.03) 0.91 (0.62 – 1.35) 0.95 (0.53 – 1.72) 1.63 (0.75 – 3.58)
Birth weight (kg) 0.99 (0.74 – 1.33) 1.04 (0.71 – 1.54) 0.90 (0.49 – 1.66) 0.94 (0.35 – 2.54)
Rate of well clinic visits* 1.10 (0.99 – 1.23) 1.32 (1.07 – 1.62) 1.09 (0.74 – 1.62) 1.10 (0.57 – 2.12)
Late immunisation 0.64 (0.36 – 1.17) 0.69 (0.39 – 1.22) 0.66 (0.31 – 1.40) 1.19 (0.40 – 3.54)
Multivariate
Vaccinated versus comparison group 0.90 (0.64 – 1.25) 1.01 (0.61 – 1.67) 0.83 (0.41 – 1.66) 0.56 (0.19 – 1.62)
Age at first examination (days) 0.98 (0.97 – 0.99) n/a n/a n/a
Rate of non-respiratory illness* 1.14 (0.83 – 1.56) 1.04 (0.71 – 1.52) 1.09 (0.58 – 2.07) 1.04 (0.42 – 2.60)
Rate of well clinic visits* n/a 1.32 (1.05 – 1.65) n/a n/a
Note: 150 episodes of first OME in 160 participants, 91 episodes of first AOM in 127 participants, 38 episodes of first TMP in 135 participants, 15 
episodes of first CSOM in 145 participants.
* (per month).
n/a not applicable.BMC Pediatrics 2009, 9:14 http://www.biomedcentral.com/1471-2431/9/14
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replacement disease following 7PCV[22,25,26]. Limited
serotype coverage of 7PCV (50% of comparison group
perforations) also contributed to poor vaccine effective-
ness. Finally, early age of onset (90% experienced OME
and 50% experienced AOM by age 4 months; before the
second dose of 7PCV) largely precludes an immunologi-
cal response to vaccination affecting development of OM.
Nonetheless, our finding that vaccinated children had
fewer recurrent episodes of TMP suggests that a schedule
stimulating an immune response before ear disease is
established, e.g. maternal, neonatal or young infant dos-
ing, may be more effective than a 2, 4, 6 month schedule.
Although our study did not follow children for a sufficient
duration to examine the effect of the 23PPV booster,
immunogenicity has been demonstrated[27] with the
potential to widen the serotype coverage beyond the 7
serotypes included in the 7PCV. Earlier administration of
the booster may be more effective than the 18 month dose
although it remains unknown whether boosting with the
7PCV or 23PPV is more effective.
Our study was designed to detect expected large effects.
Our results, are however, consistent with more modest
effects which would still be important in this population.
A further limitation is the use of historic comparisons,
which raises the possibility of bias or confounding. Uni-
versal vaccination precluded the use of concurrent con-
trols. Although there are limitations, the study setting and
measures we have taken, minimise the limitations. Bias
due to temporal changes is limited as historic data (1996–
2001) are continuous with data collected after vaccine
introduction (2001–2004). Ecological data suggested
reduced household crowding over time but no change in
levels of income, unemployment or the proportion of
Kaplan-Meier curves for time to first event Figure 2
Kaplan-Meier curves for time to first event. Time to first: OME (A), AOM (B), TMP (C) and CSOM (D).
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young children in the population. Bias towards a positive
vaccine effect due to temporal improvements in child care
practices, health services (e.g. more intensive antibiotic
schedules) and environmental conditions is possible,
however this was not evident from clinical characteristics
before 6 months of age (Tables 1 &2), nor from the essen-
tially non-significant effect that was observed. Potential
confounding is reduced as otitis risk factors are universal
in this population: breast feeding, absence of pacifiers,
family history of otitis and extremely high rates of smok-
ing. Study procedures were objective and held constant
throughout the study period. We partially adjusted for
potential bias of historic comparisons by adjusting for
rates of non-respiratory illness as a surrogate measure of
general ill health. Enrolment of 80% of the population in
the vaccinated group and 54% in the comparison group,
who were also involved in OM-RCT with more restrictive
inclusion criteria and supervised therapy, introduced
selection bias against a positive vaccine effect.
Table 6: Pathogens isolated from new tympanic membrane perforations
Perforation pathogen category Vaccinated
N = 97 (194 ears)
Comparison
N = 51 (102 ears)
New perforations 73 (38% of ears) 72 (71% of ears)
New perforation discharge specimen collected 59/73 (81% new perforations) 44/72 (61% new perforations)
Positive discharge specimens* 32/59 (54% specimens) 25/44 (57% specimens)
S. pneumoniae 19/32 (59% positive specimens) 16/25 (64% positive specimens)
All vaccine-types 7 (22%) 8 (32%)
Serotype 6B 2 (3%) 5 (20%)
All vaccine-related types 6 (19%) 2 (8%)
Serotype 19A 4 (13%) 2 (8%)
All non-vaccine types 9 (28%) 6 (24%)
Serotype 16F 4 (13%) 2 (8%)
H. influenzae 28 (88%) 21 (84%)
M. catarrhalis 0 (0%) 2 (8%)
S. pneumoniae & H. influenzae† 15 (47%) 12 (48%)
* Isolation of S. pneumoniae, H. influenzae or M. catarrhalis.
† Cases of co-infections of H. influenzae and S. pneumoniae have also been included in the numbers for individual pathogens.
Other serotypes isolated: vaccinated group 19F (3), 6A (2), 7C (2), 23F, 3, 7F, 1 & 19F co-isolated. comparison group 23F (2), 11A (2), 9V, 7F, 13.
Table 5: Incidence of AOM and TMP in vaccinated and comparison groups, including sensitivity analyses
AOM TMP
Baseline analysis Sensitivity analysis Baseline analysis Sensitivity analysis
Vaccinated Comparison Vaccinated Comparison Vaccinated Comparison Vaccinated Comparison
No. of participants 90 37 97 51 94 41 97 51
Examinations per 
year
11.53 11.80 10.24 10.20 10.77 11.70 10.03 10.20
No. of episodes 104 45 139 87 35 23 37 33
No. with 0 
episodes (%)
29 (32) 9 (24) 24 (25) 6 (12) 70 (74) 30 (73) 71 (73) 34 (67)
No. with 1 episode 
(%)
28 (31) 14 (38) 28 (29) 17 (33) 16 (17) 3 (7) 18 (19) 6 (12)
No. with >1 
episodes (%)
33 (37) 14 (38) 44 (45) 28 (55) 8 (8) 8 (19) 8 (8) 11 (22)
Unadjusted 
incidence
1.87/yr 2.05/yr 1.68/yr 2.02/yr 0.55/yr 0.82/yr 0.44/yr 0.77/yr
Adjusted incidence* 1.83/yr 2.03/yr 1.62/yr 2.02/yr 0.47/yr 0.75/yr 0.39/yr 0.75/yr
Absolute rate 
reduction†
-0.20/yr -.40/yr -0.28/yr -0.36/yr
* Adjusted in multivariate poisson model considering repeated events.
† Absolute rate reduction is the incidence in the vaccinated minus incidence in the comparison group.
Baseline analyses of incidence of AOM and TMP included participants if the first examination was at less than 4 months and less than 6 months 
respectively, and included follow-up data if repeated examinations were less than 2 months apart. Sensitivity analyses included participants with any 
age at first examination, and included follow-up data if repeated examinations were less than 4 months apart.BMC Pediatrics 2009, 9:14 http://www.biomedcentral.com/1471-2431/9/14
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Conclusion
Due to potential confounding and bias, the results of this
study should be interpreted with caution. Despite the
association of infant pneumococcal vaccination with pos-
sible reductions in incidence of AOM and TMP, the cumu-
lative proportion of Aboriginal children experiencing
OME, AOM, TMP and CSOM was unchanged as was the
time to development of different OM outcomes. Of note,
the lack of vaccine effectiveness to substantially reduce
proportions of participants experiencing different OM
outcomes and delayed onset of OM does not imply evi-
dence of no effect. This vaccination is unlikely to reduce
the prevalence of ear disease in this population in the first
years of life. Our findings have important implications for
the generalisability of research conducted in affluent pop-
ulations for high-risk disadvantaged populations. This
assertion is supported by data from Navajo and White
Mountain Apache infants, where 7PCV efficacy against
clinically-diagnosed and severe OM was somewhat
lower[10] than in Californian[6] and Finnish[7] children.
Results of post-7PCV licensure studies among affluent
populations regarding OM[26,28,29], pneumonia[30]
and invasive disease[31] have been very positive. How-
ever, 7PCV may have little effect against simple and sup-
purative ear disease and pneumonia[32] in populations at
very high risk of pneumococcal infection and those living
in disadvantaged conditions which attribute such risk.
Further study of infant cohorts is necessary to document
longer term vaccine effectiveness which incorporates
potentially increasing indirect effects over time. Thus, the
results of efficacy studies and licensing and use of a 10-
valent pneumococcal-Haemophilus  protein D conjugate
vaccine, similar to a product shown effective against OM
in Europe[20], and a 13-valent PCV[33] are much antici-
pated. Post-introduction studies of sufficient size, will be
needed to better define the impact of these vaccines
against complicated OM in the Aboriginal population.
Apart from wider serotype coverage (particularly serotypes
19A, 6A and 16F), other potential avenues to improve the
effectiveness of pneumococcal vaccines in this population
include: maternal, neonatal or young infant vaccination
and development of common pneumococcal antigen vac-
cines. Vaccines with efficacy against OM due to multiple
pathogens are also needed. In the meantime, there should
be ongoing focus on early detection and treatment of ear
disease and hearing impairment, and the underlying, pre-
dominantly social and economic, determinants of ear
infections in Aboriginal Australians.
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